Cisplatin, ara-C and etoposide (PAE) in the treatment of recurrent childhood brain tumors.
Sixteen patients with recurrent childhood brain tumors were treated with intravenous cisplatin, cytosine arabinoside and etoposide (PAE), daily for three days every three to four weeks. Objective responses were observed in 6 of 15 evaluable patients and an additional six patients had stable disease for greater than 6 months. The tumor-specific response rate for astrocytoma/glioma was 3 of 7 and for medulloblastoma was 2 of 4. The mean progression-free interval was 11.0 months and the hazard rate for progression was 0.085 per patient-month of observation. The most common toxicities were neutropenia and thrombocytopenia. Clinically significant ototoxicity was identified in 7 patients. The activity of PAE chemotherapy for recurrent childhood brain tumors warrants further investigation.
Johns Hopkins Oncology Center, Baltimore, MD.
B J
BJ
Corden
L C
LC
Strauss
T
T
Killmond
B S
BS
Carson
M D
MD
Wharam
A J
AJ
Kumar
S
S
Piantadosi
P A
PA
Robb
P C
PC
Phillips
D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use / Q000633:toxicity*; D001254:Astrocytoma / Q000188:drug therapy; D001932:Brain Neoplasms / Q000188:drug therapy*; D002528:Cerebellar Neoplasms / Q000188:drug therapy; D002648:Child; D002945:Cisplatin / Q000008:administration & dosage; D003561:Cytarabine / Q000008:administration & dosage; D004341:Drug Evaluation; D004806:Ependymoma / Q000188:drug therapy; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D005910:Glioma / Q000188:drug therapy; D006801:Humans; D008297:Male; D008527:Medulloblastoma / Q000188:drug therapy; D009364:Neoplasm Recurrence, Local; D010871:Pinealoma / Q000188:drug therapy; D011336:Probability; D011379:Prognosis
D003561:Cytarabine; D005047:Etoposide; D002945:Cisplatin